Suven Life Sciences Reallocates Rs 7,500 Lakh Preferential Issue Proceeds to Pipeline Development
Suven Life Sciences Ltd 路 Others (Uncategorized) 路 06 Nov 2026, 9:51 pm
Suven Life Sciences Reallocates Rs 7,500 Lakh Preferential Issue Proceeds to Pipeline Development Suven Life Sciences reported total utilization of Rs 53,763.36 lakh out of its Rs 85,764.02 lakh preferential issue proceeds up to 30th Sep'26, with Rs 12,813.06 lakh deployed during the quarter. Unutilized funds of Rs 32,000.66 lakh remain predominantly parked in fixed deposits and mutual funds. Shareholders approved a reallocation of Rs 7,500.00 lakh on 25th Aug'26, shifting capital from new R&D centre capex (reduced to Rs 12,500.00 lakh) to clinical development pipeline molecules at Suven Neurosciences (increased to Rs 47,500.00 lakh).
Original exchange filing (PDF)
More announcements from Suven Life Sciences Ltd
- Please find enclosed the Revised News Release of our company 路 16 Nov 2026
- Please find enclosed the News Release of our Company 路 16 Nov 2026
- Please find enclosed News Release of our Company 路 12 Nov 2026
- Un-audited financial results for the quarter and half year ended 30th September 2026 路 05 Nov 2026
- Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026 路 05 Nov 2026
- Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
- SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
